Global Acute Myeloid Leukemia Treatment Market Size to Grow at a CAGR of 11.4% During the Forecast Period of 2023-2031

Global Acute Myeloid Leukemia Treatment Market Size to Grow at a CAGR of 11.4% During the Forecast Period of 2023-2031

The ‘Global Acute Myeloid Leukemia Treatment Market Price, Size, Share, Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global acute myeloid leukemia treatment market, assessing the market on the basis of its segments like diagnosis method, therapy type, treatment channel, and major region.

The report studies the latest updates in the market, along with their impact across the market. It also analysis the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.

Acute Myeloid Leukemia Treatment Market Share, Size, Price, Growth, Trends, Industry Report, Key Player, Major Segments and Forecast

The key highlights of the report include:

Market Overview (2016-2031)

  • Forecast CAGR (2023-2031): 11.4%

Treatments for acute myeloid leukaemia (AML) are constantly changing to keep up with the increase in cases. In the past few years, there has been a significant increase in the number of cases of acute myeloid leukaemia. As people age, bone marrow cancer risk increases and in between the ages of 75 and 84, both men and women have seen a sharp rise in its incidence. Acute myeloid leukaemia cases are on the rise, even in infants and is a common diagnosis for children with leukaemia. As a result, the rising number of AML patients is driving the global acute myeloid leukemia treatment market growth.

Get a Free Sample Report with Table of Contents@

The rising preference for advanced therapies for the early diagnosis and treatment of acute myeloid leukaemia offers immense potential for market expansion. The high incidence and prevalence of acute myeloid leukaemia, developments in pharmacology and molecular biology to support medication discovery, and rising spending by pharmaceutical companies in research and development are the main drivers of the global acute myeloid leukemia treatment market growth.

Acute Myeloid Leukemia Treatment Industry Definition and Major Segments

Acute myeloid leukaemia (AML) is a specific kind of blood cancer that starts in the bone marrow and spreads throughout the blood, spleen, central nervous system, and other parts of the body while impairing the normal production of white blood cells. The rapid development of immature leucocytes known as leukemic blasts is used to identify the condition. AML requires immediate medical attention since it spreads more swiftly than other chronic conditions.

Read Full Report with Table of Contents@

Based on diagnosis method, the market is segmented into:

  • Biopsy and Bone Marrow Aspiration
  • Complete Blood Count (CBC) and Differential
  • Philadelphia Chromosome’s Presence
  • Spinal Tap (lumbar puncture) and Cerebrospinal Fluid (CSF) Analysis
  • Immunophenotyping or Phenotyping by Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Others

On the basis of therapy type, the market is categorised into:

  • Targeted Drugs
  • Chemotherapy
  • Stem/Bone Marrow Transplant
  • Radiation Therapy
  • Others

Based on treatment channel, the market is bifurcated into:

  • Public
  • Private

On the basis of region, the market is divided into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Acute Myeloid Leukemia Treatment Market Trends

Globally, the increasing geriatric population is anticipated to result in an increase in cases of AML, resulting in a heightened demand for acute myeloid leukemia treatment during the forecast period. The expansion of healthcare networks with more hospitals and speciality clinics being built is a key trend in the acute myeloid leukemia treatment market. Pharmaceutical firms are also releasing updated medicine formulations in an effort to reduce the incidences of basal cell carcinoma.

In the Asia Pacific, increases in cases of AML have prompted a surge in clinical trials for novel leukaemia treatments. The primary form of treatment for AML is still chemotherapy, and scientists are attempting to improve its effectiveness and lessen its side effects which is aiding the acute myeloid leukemia treatment market growth. Chemotherapy uses potent chemicals to eradicate malignant cells from the patient’s body, however, can lead to severe side effects.

For acute myeloid leukemia treatment, the goal is to help the patient achieve total remission, where there are less than 5% blast cells in bone marrow. The probability of achieving remission for any patient depends upon a variety of factors such as medical history, age, and stage of condition, based upon which the treatment is prescribed. Success rates and risk rates may vary, for example, stem cell transplant, as an acute myeloid leukemia treatment method, has high chances of success, but also higher risks.

Key Market Players

The major players in the global acute myeloid leukemia treatment market report are Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., Oncolyze Inc., Syndax Pharmaceuticals Inc., AbbVie Inc., Amgen Inc., Servier Pharmaceutical LLC, F. Hoffmann-La Roche Ltd, Viracta Therapeutics, Inc., Novartis AG, and Otsuka Holdings Co. Ltd. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, healthcare and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact:

Company Name: Claight Corporation
Contact Person: Steven Luke, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA


Leave a Reply

Your email address will not be published. Required fields are marked *